[Mechanism concerning antitumor effect of oridonin on multiple myeloma cell line U266].
This study was purposed to investigate the antitumor effect of oridonin on human multiple myeloma cell line U266 and its possible mechanism. The CCK-8 test was used to determine the inhibitory effect of oridonin on proliferation of U266 cells. The morphological changes of U266 cells were observed under optical microscope. The apoptosis rate of U266 cells was detected by flow cytometry. The mRNA levels of FGFR3, BCL2, CCND1 and MYC genes were quantified by using real-time quantitative PCR method, and the protein levels of BCL2, MYC, CCND1, FGFR3 and P53 were detected by Western blot. The results showed that the oridonin obviously inhibited the growth of U266 cell in dose-and time-dependent manners. As for morphological changes, characteristic apoptotic cells presented in U266 cells treated with 10 µmol/L oridonin for 24 hours. The apoptotic rate of U266 cells increased in dose and time dependent manners; after treatment of U266 cells with oridonin the mRNA levels of FGFR3, BCL2, CCND1 and MYC as well as the their protein levels decreased. Occasionally, the oridonin up-regulated the protein levels of P53 in the same manner. It is concluded that the oridonin can exert its anti-tumor effect by inhibiting proliferation and inducing apoptosis of U266 cell in dose dependent and time dependent manners, that maybe give the clues about new program of target therapy for multiple myeloma.
College of Laboratorial Medicine and College of Life Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China; Department of Clinical Laboratorial Examination, Chinese PLA General Hospital, Bejing 100853, China.
Hao-Qing
HQ
Duan
Department of Clinical Laboratorial Examination, Chinese PLA General Hospital, Bejing 100853, China.
Mian-Yang
MY
Li
Department of Hematology, China-Japanese Friendship Hospital,Beijing 100029, China.
Li
L
Gao
Department of Hematology, China-Japanese Friendship Hospital,Beijing 100029, China.
Jun-Feng
JF
Zhang
Department of Hematology, China-Japanese Friendship Hospital,Beijing 100029, China.
Wei
W
Wang
Department of Hematology, China-Japanese Friendship Hospital,Beijing 100029, China.
Yan
Y
Li
Department of Hematology, China-Japanese Friendship Hospital,Beijing 100029, China.
Yi-Gai
YG
Ma
College of Laboratorial Medicine and College of Life Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China; Department of Clinical Laboratorial Examination, Chinese PLA General Hospital, Bejing 100853, China. E-mail: wangcb301@126.com.
Cheng-Bin
CB
Wang
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D045786:Diterpenes, Kaurane / Q000494:pharmacology*; D006801:Humans; D009101:Multiple Myeloma / Q000473:pathology
D000970:Antineoplastic Agents; D045786:Diterpenes, Kaurane; C011959:oridonin